✦ LIBER ✦

Pharmacokinetics and biological activity in subcutaneous long-term administration of recombinant interferon-γ in cancer patients

✍ Scribed by W. Digel; G. Zahn; G. Heinzel; F. Porzsolt

Publisher: Springer-Verlag
Year: 1991
Tongue: English
Weight: 741 KB
Volume: 34
Category: Article
ISSN: 0340-7004
DOI: 10.1007/bf01742308

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Subcutaneous recombinant gamma interfero

Subcutaneous recombinant gamma interferon in cancer patients: toxicity, pharmacokinetics, and immunomodulatory effects

✍ John A. Thompson; W. Welby Cox; Catherine G. Lindgren; Carolyn Collins; Kathryn 📂 Article 📅 1987 🏛 Springer-Verlag 🌐 English ⚖ 750 KB

Recombinant gamma interferon (ry-IFN) was administered s. c. daily to 26 patients with advanced cancer. Patients were assigned to one of six doses: 0.5, 1, 2, 4, 6, or 8 million units (MU)/m 2 per d. The major toxicities were an influenza-like syndrome and fever, seen in all patients. Dose limiting

Recombinant human γ-interferon in patien

Recombinant human γ-interferon in patients with chronic active hepatitis B: Pharmacokinetics, tolerance and biological effects

✍ Patrick Marcellin; Marie-Anne Loriot; Nathalie Boyer; Michéle Martinot-Peignoux; 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 397 KB

Pharmacokinetics, tolerance and biological effects of human recombinant y-interferon were studied in 12 patients with chronic active hepatitis B. Serum concentrations of y-interferon were measured by radioimmunoassay in four patients after a subcutaneous injection of 10 million U (0.6 mg); the peak

Long-term pharmacokinetics of thio-TEPA,

Long-term pharmacokinetics of thio-TEPA, TEPA and total alkylating activity following i. v. bolus administration of thio-TEPA in ovarian cancer patients

✍ Bjørn Hagen; Gunhild Neverdal; Rolf A. Walstad; Odd G. Nilsen 📂 Article 📅 1990 🏛 Springer 🌐 English ⚖ 603 KB

Activation of peritoneal macrophages in

Activation of peritoneal macrophages in patients with gynecological malignancies by sizofiran and recombinant interferon-γ

✍ Jui -Tung Chen; Katsuhiko Hasumi 📂 Article 📅 1993 🏛 Springer 🌐 English ⚖ 829 KB

Recombinant leukocyte a interferon (rIFN

Recombinant leukocyte a interferon (rIFN-αA) in the treatment of disseminated malignant melanoma: Analysis of complete and long-term responding patients

✍ Edward T. Creagan; David L. Ahmann; Stephen Frytak; Harry J. Long; Loretta M. It 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 296 KB 👁 1 views

Activation of 2′,5′-oligoadenylate synth

Activation of 2′,5′-oligoadenylate synthetase and B-2 microglobulin in cancer patients treated with partially pure gamma interferon: Dependence of biological effect on administration route

✍ Michel G. Rosenblum; Adan Riso; Jordan U. Gutterman 📂 Article 📅 1986 🏛 Springer 🌐 English ⚖ 425 KB

Partially pure immune (gamma) interferon (IFN-gamma) was administered to patients intramuscularly (IM), by rapid IV bolus, and by 6-h continuous infusion as part of a phase I clinical trial. The activity of 2',5'-oligoadenylate synthetase (2,5 A) in peripheral blood cells and the concentration of be